Literature DB >> 21397310

Association of anti-IgA antibodies with adverse reactions to γ-globulin infusion.

Rima Rachid, Mariana Castells, Charlotte Cunningham-Rundles, Francisco A Bonilla.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21397310      PMCID： PMC3129450          DOI： 10.1016/j.jaci.2011.01.061

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  9 in total

1.  Use of an IgA-depleted intravenous immunoglobulin in a patient with an anti-IgA antibody.

Authors:  C Cunningham-Rundles; S Wong; J Björkander; L A Hanson
Journal:  Clin Immunol Immunopathol       Date:  1986-02

2.  Follow-up of anti-IgA antibodies in primary immunodeficient patients treated with gamma-globulin.

Authors:  A Ferreira; M C García Rodriguez; G Fontán
Journal:  Vox Sang       Date:  1989       Impact factor: 2.144

3.  Immunoglobulin substitution therapy in a patient with primary hypogammaglobulinaemia and anti-IgA antibodies.

Authors:  U Hedderich; G Kratzsch; W Stephen; H Dichtelmüller; K Olischläger; H Heimpel
Journal:  Clin Allergy       Date:  1986-07

4.  Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA.

Authors:  A W Burks; H A Sampson; R H Buckley
Journal:  N Engl J Med       Date:  1986-02-27       Impact factor: 91.245

5.  IgG anti-IgA subclasses in common variable immunodeficiency and association with severe adverse reactions to intravenous immunoglobulin therapy.

Authors:  R de Albuquerque Campos; M N Sato; A J da Silva Duarte
Journal:  J Clin Immunol       Date:  2000-01       Impact factor: 8.317

6.  Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin.

Authors:  V M Brennan; N J Salomé-Bentley; H M Chapel
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

7.  Hemagglutination assays for the diagnosis and prevention of IgA anaphylactic transfusion reactions.

Authors:  S G Sandler; R Eckrich; D Malamut; D Mallory
Journal:  Blood       Date:  1994-09-15       Impact factor: 22.113

8.  Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy.

Authors:  H W Eijkhout; P J van den Broek; J W M van der Meer
Journal:  Neth J Med       Date:  2003-06       Impact factor: 1.422

9.  Anti-IgA antibodies in selective IgA deficiency and in primary immunodeficient patients treated with gamma-globulin.

Authors:  A Ferreira; M C Garcia Rodriguez; M Lopez-Trascasa; D Pascual Salcedo; G Fontan
Journal:  Clin Immunol Immunopathol       Date:  1988-05
  9 in total
  8 in total

1.  International Consensus Document (ICON): Common Variable Immunodeficiency Disorders.

Authors:  Francisco A Bonilla; Isil Barlan; Helen Chapel; Beatriz T Costa-Carvalho; Charlotte Cunningham-Rundles; M Teresa de la Morena; Francisco J Espinosa-Rosales; Lennart Hammarström; Shigeaki Nonoyama; Isabella Quinti; John M Routes; Mimi L K Tang; Klaus Warnatz
Journal:  J Allergy Clin Immunol Pract       Date:  2015-11-07

Review 2.  Advances in basic and clinical immunology in 2011.

Authors:  Javier Chinen; William T Shearer
Journal:  J Allergy Clin Immunol       Date:  2011-12-28       Impact factor: 10.793

3.  Long-Term Treatment and Transfusion of Normal Blood Components Following Tolerance Induction in Patients with Anti-IgA Anaphylactic Reactions.

Authors:  Abdulgabar Salama; Romina Kardashi; Olga Arbach
Journal:  Transfus Med Hemother       Date:  2014-09-15       Impact factor: 3.747

4.  Low Serum IgE Is a Sensitive and Specific Marker for Common Variable Immunodeficiency (CVID).

Authors:  Monica G Lawrence; Thamiris V Palacios-Kibler; Lisa J Workman; Alexander J Schuyler; John W Steinke; Spencer C Payne; Emily C McGowan; James Patrie; Ramsay L Fuleihan; Kathleen E Sullivan; Patricia L Lugar; Camellia L Hernandez; Douglas E Beakes; James W Verbsky; Thomas A E Platts-Mills; Charlotte Cunningham-Rundles; John M Routes; Larry Borish
Journal:  J Clin Immunol       Date:  2018-02-17       Impact factor: 8.317

5.  Intravenous immunoglobulin and the current risk of moderate and severe anaphylactic events, a cohort study.

Authors:  Carlos Martinez; Christopher Wallenhorst; Sheryl van Nunen
Journal:  Clin Exp Immunol       Date:  2021-10-17       Impact factor: 4.330

6.  Human normal immunoglobulin in the treatment of primary immunodeficiency diseases.

Authors:  Philip Wood
Journal:  Ther Clin Risk Manag       Date:  2012-04-02       Impact factor: 2.423

Review 7.  Adverse Effects of Immunoglobulin Therapy.

Authors:  Yi Guo; Xin Tian; Xuefeng Wang; Zheng Xiao
Journal:  Front Immunol       Date:  2018-06-08       Impact factor: 7.561

8.  Systemic administration of an HIV-1 broadly neutralizing dimeric IgA yields mucosal secretory IgA and virus neutralization.

Authors:  Joshua Eudailey; Erika L Kunz; Genevieve G Fouda; Joshua D Amos; Brooke E Liebl; Jonathan Himes; Felix Boakye-Agyeman; Krista Beck; Anthony J Michaels; Michael Cohen-Wolkowiez; Barton F Haynes; Keith A Reimann; Sallie R Permar
Journal:  Mucosal Immunol       Date:  2016-04-13       Impact factor: 7.313
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.